MC-Val-Cit-OH
This product is a protease-sensitive linker consisting of maleimidocaproyl (MC), valine–citrulline (Val-Cit) dipeptide, and a terminal hydroxyl group. The Val–Cit sequence is efficiently cleaved by cathepsin B and other proteases, while the MC group provides thiol-reactive conjugation, making it a widely used intermediate in antibody–drug conjugate (ADC) linker systems.
Key Features and Benefits:
-
Maleimidocaproyl (MC): Provides thiol-reactive functionality for stable conjugation to cysteines.
-
Val–Cit Dipeptide: Cleavable by proteases such as cathepsin B for selective drug release.
-
Hydroxyl Terminus: Enables further modification or extension into drug–linker constructs.
-
Self-Immolative Mechanism: Supports efficient payload release following enzymatic cleavage.
-
High Purity: Ensures reproducibility in ADC and bioconjugation workflows.
Applications:
-
ADC Development: Core linker used in many antibody–drug conjugates for controlled drug release.
-
Drug Delivery: Enables targeted release in tumor microenvironments or intracellular compartments.
-
Bioconjugation: Facilitates thiol-based protein modification with protease-sensitive release.
-
Synthetic Chemistry: Intermediate for advanced linker–payload scaffolds.
Storage and Handling:
-
Storage: Store at –20 °C in a sealed, light-protected container.
-
Handling: Use anhydrous solvents (e.g., DMF, DMSO); avoid moisture to preserve MC reactivity.
This product combines a thiol-reactive MC handle with a protease-cleavable Val–Cit sequence, making it a cornerstone reagent specifically in ADC linker design and controlled drug delivery applications.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
